Faron Pharmaceuticals Oy · LSE:FARN

Faron Pharmaceuticals Oy — Investor Presentation (September 2021)

38 slides from Faron Pharmaceuticals Oy's investor presentation, September 2021

1. Slide 1: Leading the Way in Breakthrough Immune Therapies

   LEADING THE WAY IN BREAKTHROUGH IMMUNE THERAPIES Corporate Presentation September 2021

2. Slide 2: %%$ %$ !#$%% ' % !!# ' * &% #+ !#$ (% % %%$

   %%$ %$ !#$%% ' % !!# ' * &% #+ !#$ (% % %%$ %$ !#$%% ' % !%* '#- %%$ %$ % 76 % #'$ #%$ % 7555 2$ 3 24 43- !#$%% # $&!! % * & $ * # * &# #% * % #!# &, #1 % %%$ %$ !#$%% # % !&#! $ * '$%% %'%* $%#&% # !$$ % * %# !#$ # !&$ ( # !#% # * !&#! $- %$ * )! $ '& % $% #$ $ % !# !#%* # %# $$%$ '$%- &% $ #' ## #

3. Slide 3: %+2)-*)82#2$#0)123.13(1.63(#1*%3 .-$.-82+3%1-#3)5%-5%23,%-3#1*%3 #1*%3#/ 9 9#2.& 4-% #2( 9 -.-$)+43)5%&4-$)-' %#$04#1…

   %+2)-*)82#2$#0)123.13(1.63(#1*%3 .-$.-82+3%1-#3)5%-5%23,%-3#1*%3 #1*%3#/ 9 9#2.& 4-% #2( 9 -.-$)+43)5%&4-$)-' %#$04#13%12 41*4)-+#-$#-$.23.-! .&,/+.7%%2 "%#1.4-$%$ 60 # 86%%#$7576 70 " "%$# $/7576%%#$7:$0" ! "$# ."#* %"(6. %85*7576,1"##"#2$$!#+--'''," , -'#.&$#-'#..!"##. "##)"#=6957<;:3=7778 80 $ "$

4. Slide 4: #' !" ' ! ' "" ' ! #' #' "" $' ( %'

   #' !" ' ! ' "" ' ! #' #' "" $' ( %' ! "' #! ! ' "" ! " !

5. Slide 5: #& & % "& & ! & $!& % ' '' "'"& $ &

   #& & % "& & ! & $!& % ' '' "'"& $ & % ( ! "& %

6. Slide 6: !!! % (-# " %! " ! /,56 ( ! " % #! $

   !!! % (-# " %! " ! /,56 ( ! " % #! $ # # " ! .,/1 ! ( "! $ -2 )''&01* " ! " #%%

7. Slide 7: ! " # '#" '%"' ,$%&"'' # (!#%&0 #"%" )#' ##%'&'#"%%('!"' .55 %&'/$'"'/"+$'" 7

   ! " # '#" '%"' ,$%&"'' # (!#%&0 1 #"%" )#' ##%'&'#"%%('!"' 4.55 %&'/$'"'/"+$'" 7 -54 0 /38 1 " #()"'"# (!#%& %&'/$'"'/"+$'" 7 -54 0 1 !'# # ""& %&'/$'"'/"+$'"7-54 0 1 &4'"6.55 2 /49 %&'$'"'#&((&'.54 0 1 2 /49 " '#" '+$'75354 0 /1 !'# # ""& "'$' &(!&&#""5355 !# #" %%#* (%

8. Slide 8: Bexmarilimab (anti-CLEVER-1 mAb)

   Bexmarilimab (anti-CLEVER-1 mAb)

9. Slide 9: A CLEVER Antibody: Outsmarting Cancer with Early Signs of Efficacy

   A CLEVER Antibody: Outsmarting Cancer with Early Signs of Efficacy A unique macrophage focused therapy targeting CLEVER-1 with demonstrated single agent activity in multiple advanced solid tumors Favorable safety profile enables extensive combinations with checkpoint inhibitors Opportunity to transf

10. Slide 10: . ) ! & )1-3 $ # .+ ('*/-.4+ '%1*4+&.4-354' $)'' */-.4+ '035&/-1-)/-2. &

    . ) ! & )1-3 $ # .+ ('*/-.4+ '%1*4+&.4-354' $)'' */-.4+ '035&/-1-)/-2. & */-.5+ " '/-.5 #% /*2+&.5/202'

11. Slide 11: 3(4 5(6 6(7(8 3. "-423;. " #&*32)3833 4. !!"" -423:. "# $%!) #!$ &39-34.::9,;26

    7 3(4 5 5(6 6(7(8 3. "-423;. " #&*32)3833 4. !!"" -423:. "# $%!) #!$ &39-34.::9,;26 5. # -423:. ! # *46-7.694,6:; 6. #/ #-4243. ! * *8-349. 7. 8. "-423;. *34344,55 ' "-423:. *337-39.6263,6272 8 9. $ "-4236. *;-7.8;7,929 :. "$# "*-4243. ! #4(4243( )32*337:+329:, 2654*,42,6:84

12. Slide 12: !" - - "# ! . "# /#0#1#2 "# - ,( '-+-,( %4$++,./, -(

    !" - - "# ! . "# /#0#1#2 "# - ,( '-+-,( %4$++,./, -( %#'-+-+( %,-.%0+,&0+4 .( %#'-+,,(!% %!%/,-+0-&-+1. /( " %#'-+,4( %/,-+03&-+1/ 0( %#'-+-+(% %,4'.(-/+/&-/,- 1( '-+,4( %,-,--&.. 2( '-+,4( %% !%% /21&/3/

13. Slide 13: ug/mL

    sClever-1 P<0.0001 1.0 0.8 0.6 ug/mL 0.4 0.2 0.0 al N S m I AT or N M

14. Slide 14: Inhibition of CLEVER-1 Leads to Responses in Refractory Mice Models

    Inhibition of CLEVER-1 Leads to Responses in Refractory Mice Models Macrophages are central to tumor growth and survival ~ LLCI (Lung) 200: EL-4 (lymphoma) 300 * 150 © a0 E 100 / 100- 50- ean 0 5 10 1% 0 5 to %5 200 +} ew O Macro KO r (lyzM-Cre/Stab1") 100: Va *P<0.05 Tumors cannot grow in mice that

15. Slide 15: CLEVER-1 Expression is Associated with Survival, Therapeutic Response & T-Cell Dysfunction

    CLEVER-1 Expression is Associated with Survival, Therapeutic Response & T-Cell Dysfunction + Kaplan Meier of CLEVER-1 (STAB1) mRNA expression TCGA-PANCAN TCGA Among all cancer patients Among immunotherapy treated patients All immunotherapy treated patients 20 * KK 2 P<0.0001 ° =0.002 — a = ‘| ° . BS

16. Slide 16: Bexmarilimab's Ability to Turn Cold Tumors Hot

    Bexmarilimab’s Ability to Turn Cold Tumors Hot 23% of immune suppressed cancer patients show an IFNy response during dose finding 7 Robust T-Cell Restoration of Pro-Inflammatory 1 ; : : CD8' Pre- i 5 Treatment 70.1% 2.7% 4 IFNy o i oO a : ce} i nod ee : 5 : no 13.4%| J 29.9% 5.2%] 2 = : : o Post- :

17. Slide 17: MATINS trial design

    geo" Dr. Petri Bono MD, PhD, Chief Medical Officer, Terveystalo Finland Associate professor, University of Helsinki Principal Investigator, MATINS Trial Part I (dose finding), n=30 Dose and Safety Part Il (cohort expansion) n=10 / cohort Safety and Preliminary Efficacy Part Ill (expansion based on e

18. Slide 18: MATINS Phase I/II Top Line Data

    MATINS Phase I/II Top Line Data Cutaneous Melanoma Spider Plot Cutaneous Melanoma 1.0MG 150 4 100 4 %-Change from Baseline 0 50 100 150 200 250 Study Day of Tumor/Lesion Measurement All melanoma patients had received anti-PD-(L)1 treatment before entering the study. All patients doses with 1mg/kg Q3

19. Slide 19: MATINS Phase I/II Top Line Data

    MATINS Phase I/II Top Line Data Gastric Adenocarcinoma Spider Plot Gastric adenocarcinoma 1L.0MG oo 40 4 & 3 a 20 aa é : ge 4 = 20 + _—_ ol — ° 50 100 150 Study Day of Tumor/Lesion Measurement All patients doses with 1mg/kg Q3W 19 Faron Pharm:

20. Slide 20: "& )' $! " "% & "$ # "$ !( ! !( ! !)

    "& )' $! " "% & "$ # "$ !( ! !( ! !) ! ' !& !! ! !" %%&'( "& *'# !($ *

21. Slide 21: +",.3%+"+./$+"020& $ $ !$ , ,& %-+-,-1& $ ,$ .+ -+-,' (!##" " #$#$

    +",.3%+"+./$+"020& $ $ !$ , ,& %-+-,-1& $ ,$ .+ -+-,' (!##" " #$#$ $$ 4,0+-321) 4---.

22. Slide 22: % % ""! % "! " % 3- $ % 4- ! ,4243!47 -

    % % ""! % "! " % 3- $ % 4- ! ,4243!47 - +'!$3+ !52'4243. / (**###))*#+ " *#+++&:36249870:4445

23. Slide 23: $$#$ $ #, " !".!" " #$ &$ $% " #" % ./ $"$

    $$#$ $ #, " !".!" " #$ &$ $% " #" % ./ $"$ !$')$ %#( $ !!" &#" !" . #%"&&#$ #$%" ##$+!& $$"#' !.#$%# !$$###$ $ ")&# . (%$- $ ")$% "# %!!" &#" "#$" !". !%$ #"' " * $" !" "$$ # ' "#! # "$ "%# $ #$$## ' $ #$$&$) "#$ #'$$../ $ $"!) ($")'$ "$ $.0 "#$$"$"#$ ! #$##& !$ "! "$$ $!& $(!# $ "$#$ ""$"#""$ #'" !

24. Slide 24: #$ ! &!" !$! $ ( # &( $%& % ' #$ " !$

    #$ ! &!" !$! $ ( # &( $%& % ' #$ " !$ ' $& #" $" %" &" !"

25. Slide 25: !!! % (-# " %! " ! /,56 ( ! " % #! $

    !!! % (-# " %! " ! /,56 ( ! " % #! $ # # " ! .,/1 ! ( "! $ -2 )''&01* " ! " #%%

26. Slide 26: Traumakine (Intravenous IFN beta-1a)

    Traumakine (Intravenous IFN beta-1a)

27. Slide 27: Interferon Beta: A Well-Known Drug with a Novel Approach

    Interferon Beta: A Well-Known Drug with a Novel Approach A potential orphan blockbuster with a path to approval in a critical care discipline Potentially first innovative drug to be approved in ARDS to sustain lung function significantly increase the adoption of CAR-T therapy Clear route to market w

28. Slide 28: Interferon Beta Induces CD73 for Organ Protection

    Interferon Beta Induces CD73 for Organ Protection An effective pharmacotherapy for producing anti-inflammatory adenosine Pro-inflammatory Anti-inflammatory : Adenosine Capillary fs Red blood cells ETP Capillary leakage Leukocyte CD39 cD73 Adenosine Interteron CD73 Leukocyte B expression Maximising t

29. Slide 29: ! ! " # )& % -&- (-2 !& " $ ! "# !

    ! ! " # )& % -&- (-2 !& " $ ! "# ! . "")- $,$$%#$24 +'#$ "&$#% ""$) ")- $#, "$$)$36+")#$36+$$")# "% #$%""$#$" ".($#/'&") * #,241 $$# .$""%$$51:"$/ # $* -27 $$# '$ %##$"#$#$#+%$#$"#%#$" $ )$"!%"&$$ ")" )'$$""$#)$ "&$$& $"$## (* $(& (&(' -* $).,.-*'"' $% '.-1)-,*.,.--.--.*! !'0.)-*/-(00 ).,.-*

30. Slide 30: Haematokine (AOC3 Inhibitor)

    Haematokine (A0C3 Inhibitor)

31. Slide 31: Haematokine: Driving Stem Cell Expansion

    Haematokine: Driving Stem Cell Expansion The Founding Team discovered VAP-1 and has nearly 30 years of experience with the target + Bone Marrow Transplants fail in over 25% of patients Cancer Patients frequently have high levels of VAP-1 High Unmet Need in patients requiring stem cell transplantatio

32. Slide 32: Targeting VAP-1 for Stem Cell Expansion and Anti-Tumor Activity

    Targeting VAP-1 for Stem Cell Expansion and Anti-Tumor Activity A collaborative science discovery from Stanford University and Turku University Haematokine’s Benefit CD38-CD34*CDA5RACD90"CDA9F* * KA Easier transplantation for older and impaired patients “1600; . 5 flono ¥ suffering from MDS and AML

33. Slide 33: Corporate Highlights

    Corporate Highlights

34. Slide 34: '#*&-## ) #!!& &$&(#" #$ "(&#! '3 &!()&** "(+''""&'$#""$("(' (#"#,$"'#"##&('1'(&.# "#&"#!. "#!" 2 -

    '#*&-## ) #!!& &$&(#" #$ "(&#! '3 &!()&** "(+''""&'$#""$("(' (#"#,$"'#"##&('1'(&.# "#&"#!. "#!" 2 - "( () &#$&(-1#"&!(#"# ((&2+& #&) (#"#'3(" " "&'& (#"# 03("""(0#-"$("(('')'!$ ' $(& &'"((#"()&#$"#(-# "# #- (#" (& '#" '# ()!#&'"5/43 #"&!(#"#" #'"&%)"-#&$*#( ,$"'#" *#( ##&('(#"&&)(!"(" 3/44 &'(0$("(0

35. Slide 35: % % %! !! '+* % ( ! # ( !# !& , #

    % % %! !! '+* % ( ! # ( !# !& , # $""! " ! !+)++

36. Slide 36: !!! % (-# " %! " ! /,56 ( ! " % #! $

    !!! % (-# " %! " ! /,56 ( ! " % #! $ # # " ! .,/1 ! ( "! $ -2 )''&01* " ! " #%%

37. Slide 37: $ !% !! #" !" ! # " ! # ! $$! "! "!

    $ !% !! #" !" ! # " ! # ! $$! "! "! & ! "" !% " ! # "' (

38. Slide 38: Thank you

Faron Pharmaceuticals — Investor Presentation (September 2021) on 6ix